Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from ...
HC Wainwright & Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $8 price target.
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $...
Plus Therapeutics (NASDAQ:PSTV) reported quarterly sales of $1.28 million which missed the analyst consensus estimate of $1.68 ...
The data were presented in a podium presentation at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Onco...
The Company received notice of an advance payment of $3.3 million from CPRIT, part of the $17.6 million award granted in Septem...
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1...
CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rh...
